PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
Modern Pathology2010Vol. 24(3), pp. 443–452
Citations Over TimeTop 17% of 2010 papers
Laia Agell, Sílvia Hernández, Marta Salido, Silvia de Muga, Núria Juanpere, Montserrat Arumí-Uría, Sílvia Menéndez, Marta Lorenzo, José A. Lorente, Sérgio Serrano, Josep Lloreta
Related Papers
- → Drugging All RAS Isoforms With One Pocket(2020)73 cited
- → Multiplexed screens identify RAS paralogues HRAS and NRAS as suppressors of KRAS-driven lung cancer growth(2023)31 cited
- → Targeting the KRAS α4-α5 allosteric interface inhibits pancreatic cancer tumorigenesis(2021)15 cited
- → Kras and Hras—what is the difference?(2008)11 cited
- → Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy(2023)5 cited